Group 1 - The core focus of the news is the recent institutional research conducted on Innovation Medical Management Co., Ltd., highlighting the advancements and product offerings of its subsidiary, Bole Brain Machine [1][2] - The research event took place on September 25, with participation from eight institutions, including Guohai Securities and Dongwu Securities, showcasing the company's commitment to transparency and engagement with investors [1] - Bole Brain Machine's C-end product, Cyberlink AC5, features user-friendly design and advanced brain-machine interface technology, aimed at improving the quality of life for patients with motor impairments [1][2] Group 2 - Clinical trials for the medical version of Bole Brain Machine's products are progressing well, with over 100 patient tests completed, showing significant improvements in motor function for both new and long-term patients [2] - The C-end product weighs 1.5 kg and includes two batteries with a six-hour lifespan each, designed for daily use and convenience for patients [2] - Future product development includes plans for lower limb rehabilitation products and a focus on invasive technology routes, with ongoing research into intelligent peripheral nerve stimulation systems [2][3] Group 3 - The C-end product is priced based on the value it provides to hemiplegic patients, potentially saving families 40,000 to 60,000 yuan annually in the Jiangsu, Zhejiang, and Shanghai regions [3] - Innovation Medical holds a 68.356% stake in Bole Brain Machine, which is included in the company's consolidated financial statements, indicating a strong financial interest in the subsidiary's success [3]

Group 1: Company Overview and Event Details - The investor relations activity was conducted as a live performance, showcasing the subsidiary Boling Brain Machine's introduction video and product demonstrations [2] - The event took place on September 25, 2025, at the Innovation Medical Hangzhou branch [2] Group 2: Product Features and Clinical Testing - Boling Brain Machine products are designed to be lightweight, user-friendly, and simple to operate, utilizing brain-machine interface technology to enhance patient rehabilitation [3] - Over 100 patients have participated in multi-center clinical tests, showing significant improvements in Fugl-Meyer scores for both newly diagnosed and long-term stroke patients [3][4] Group 3: Product Specifications and Future Developments - The C-end product weighs 1.5 kg and has a battery life of approximately 6 hours per battery, with two batteries included [3] - Future products include a dexterous hand for fine motor control and a pneumatic glove for gross motor actions, with ongoing research into invasive technology [4] Group 4: Economic Impact and Cost Savings - The C-end product can save families between 40,000 to 60,000 CNY annually by reducing the need for full-time caregivers [6] - Traditional rehabilitation costs can reach 65,000 CNY per year, while the Boling Brain Machine allows for home-based training, significantly lowering expenses [6] Group 5: Company Ownership and Market Position - The company holds a 68.356% stake in Boling Brain Machine, which is included in the consolidated financial statements [6]

Market Overview - The Shanghai Composite Index closed at 3821.83 points, with a decline of 0.18% [1] - The total trading volume of A-shares reached 25,184.71 billion yuan [1] Technical Analysis - A total of 171 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.60 yuan, 10-day MA at 23.25 yuan, a difference of -2.80% [1] - Xiangyu Medical: 5-day MA at 54.48 yuan, 10-day MA at 55.33 yuan, a difference of -1.54% [1] - Northern Long Dragon: 5-day MA at 122.21 yuan, 10-day MA at 123.92 yuan, a difference of -1.38% [1] Stock Performance - Key stocks with notable declines include: - Innovation Medical: down 2.97% with a turnover rate of 16.99% [1] - Xiangyu Medical: down 5.95% with a turnover rate of 2.14% [1] - Northern Long Dragon: down 2.23% with a turnover rate of 20.67% [1] - Other stocks with significant declines include: - Aorui: down 5.25% [1] - Changbai Mountain: down 7.15% [1] - Hengbao Shares: down 6.73% [1]

Market Overview - The Shanghai Composite Index closed at 3781.61 points, with a decline of 1.23% [1] - The total trading volume of A-shares reached 1713.539 billion yuan [1] Technical Analysis - A total of 228 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.55 yuan, 10-day MA at 23.23 yuan, a difference of -2.92% [1] - North Long Dragon: 5-day MA at 121.67 yuan, 10-day MA at 123.65 yuan, a difference of -1.60% [1] - Xiangyu Medical: 5-day MA at 54.49 yuan, 10-day MA at 55.34 yuan, a difference of -1.53% [1] Individual Stock Performance - Significant declines in stock prices include: - Innovation Medical: down 4.27% with a turnover rate of 14.36% [1] - North Long Dragon: down 4.52% with a turnover rate of 13.85% [1] - Xiangyu Medical: down 5.86% with a turnover rate of 1.42% [1] - Other notable declines: - Shandong Mining Machine: down 4.43% [1] - Huakang Clean: down 6.50% [1] - Beautiful Ecology: down 5.15% [1] Additional Stock Data - The following stocks also showed significant declines: - Yuyin Co.: down 5.46% [2] - Kexin Information: down 5.22% [1] - Visual China: down 3.88% [1] - Stocks with notable trading activity include: - Hengbao: down 6.64% with a turnover rate of 10.88% [2] - Changbai Mountain: down 6.53% with a turnover rate of 4.05% [2]

Group 1 - The A-share market saw a significant decline in brain-computer interface concept stocks, with several companies experiencing drops of over 5% [1] - Notable companies that fell over 5% include Dineike, Xiangyu Medical, Meihao Medical, Chengdu Huamei, and Tom Cat [1] - Other companies such as Yanshan Technology, Zhongke Information, Aipeng Medical, Nanjing Panda, Weisi Medical, Innovation Medical, Robot, Mailande, Beiqingsong, Botuo Biological, and Rongtai Health dropped over 4% [1]

Core Viewpoint - The A-share market is experiencing a decline, with the Shanghai Composite Index down by 1.12% and a total trading volume of 1,274.25 billion yuan as of 10:30 AM [1] Group 1: Market Performance - The Shanghai Composite Index is at 3,785.77 points, reflecting a decrease of 1.12% [1] - The total trading volume in the A-share market is 1,274.25 billion yuan [1] Group 2: Technical Indicators - A total of 236 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA down by 3.16% from 10-day MA [1] - Beautiful Ecology: 5-day MA down by 1.66% from 10-day MA [1] - Jiayun Technology: 5-day MA down by 1.65% from 10-day MA [1] Group 3: Individual Stock Performance - Innovation Medical (002173) is down 6.83% with a latest price of 20.06 yuan, showing a deviation of -13.43% from the 10-day moving average [1] - Beautiful Ecology (000010) is down 7.83% with a latest price of 4.12 yuan, showing a deviation of -11.34% from the 10-day moving average [1] - Jiayun Technology (300242) is down 4.48% with a latest price of 4.05 yuan, showing a deviation of -7.11% from the 10-day moving average [1]

Group 1 - The core viewpoint of the article is the strategic partnership between Meinian Health Group and Beijing Guoping Innovation Medical Technology Co., Ltd. to enhance health management services [1] - The collaboration will focus on areas such as health check-ups, chronic disease rehabilitation, medical care, and health management services for both enterprises and individuals [1]

Group 1 - The high-pressure oxygen chamber concept declined by 1.90% as of the market close on September 22, ranking among the top declines in concept sectors, with companies like Hangzhou Oxygen, Innovative Medical, and China Railway Construction showing significant drops [1] - The high-pressure oxygen chamber sector experienced a net outflow of 238 million yuan from main funds today, with seven stocks seeing net outflows, and five stocks exceeding 10 million yuan in outflows. Innovative Medical led with a net outflow of 126 million yuan, followed by China Railway Construction and Hangzhou Oxygen [2] - The top stocks with net outflows in the high-pressure oxygen chamber sector included Innovative Medical (-4.18%), China Railway Construction (-2.36%), and Hangzhou Oxygen (-4.56%), with respective main fund outflows of 126.14 million yuan, 53.78 million yuan, and 21.64 million yuan [2] Group 2 - The concept sectors with the highest gains today included Tonghuashun Fruit Index (+5.17%), AI Mobile Phones (+4.06%), and Smart Speakers (+3.43%), while the high-pressure oxygen chamber sector was among the top decliners [2] - The main fund inflows were observed in stocks like Jinling Pharmaceutical, Weiao Co., and Dahu Co., with inflows of 2.58 million yuan, 1.16 million yuan, and 0.95 million yuan respectively [2]

Core Viewpoint - The stock of Innovation Medical (002173) has experienced a decline, with significant net outflows from major funds, while retail investors have shown a net inflow [1][2]. Group 1: Stock Performance - As of September 22, 2025, Innovation Medical closed at 21.53 yuan, down 4.18% with a turnover rate of 14.72% and a trading volume of 612,900 hands, resulting in a transaction amount of 1.34 billion yuan [1]. - Over the past five days, the stock has seen a consistent decline, with the highest drop recorded on September 18 at 4.75% [2]. Group 2: Fund Flow Analysis - On September 22, 2025, major funds had a net outflow of 175 million yuan, accounting for 13.08% of the total transaction amount, while retail investors had a net inflow of 196 million yuan, representing 14.64% of the total [1][2]. - The trend over the past five days shows a pattern of net outflows from major and speculative funds, with retail investors consistently showing net inflows [2]. Group 3: Company Financials - Innovation Medical reported a total market value of 9.501 billion yuan, with a net asset value of 1.766 billion yuan and a net profit of -11.3613 million yuan, indicating a poor financial standing compared to the industry averages [3]. - The company's gross margin stands at 12.06%, significantly lower than the industry average of 35.92%, and the net profit margin is -2.79% compared to the industry average of 3.8% [3]. - For the first half of 2025, the company’s main revenue was 402 million yuan, a year-on-year decrease of 1.6%, while the net profit attributable to shareholders was -11.3613 million yuan, a year-on-year increase of 29.12% [3].

Core Viewpoint - Innovation Medical's stock has experienced significant fluctuations, with a year-to-date increase of 176.63% but a recent decline in the last five trading days by 9.68% [1] Financial Performance - As of June 30, 2023, Innovation Medical reported a revenue of 402 million yuan, a year-on-year decrease of 1.60%, while the net profit attributable to shareholders was -11.36 million yuan, an increase of 29.12% year-on-year [2] - The company has distributed a total of 55.87 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [2] Stock Market Activity - On September 22, 2023, Innovation Medical's stock price was 22.02 yuan per share, with a trading volume of 557 million yuan and a turnover rate of 5.99%, resulting in a total market capitalization of 9.717 billion yuan [1] - The stock has appeared on the "Dragon and Tiger List" 18 times this year, with the most recent appearance on September 5, 2023, showing a net buy of -121 million yuan [1] Shareholder Information - As of June 30, 2023, the number of shareholders for Innovation Medical was 82,000, an increase of 20.38% from the previous period, with an average of 5,074 circulating shares per shareholder, a decrease of 16.93% [2] Industry Classification - Innovation Medical is classified under the pharmaceutical and biological industry, specifically in the medical services sector, with concepts including ophthalmology, strong annual performance, QFII holdings, medical devices, and artificial intelligence [2]